Stereotactic Radiotherapy for Early Stage Non-Small Cell Lung Cancer

Current Standards and Ongoing Research

Eugenia Vlaskou Badra; Michael Baumgartl; Silvia Fabiano; Aurélien Jongen; Matthias Guckenberger


Transl Lung Cancer Res. 2021;10(4):1930-1949. 

In This Article


The advances in SBRT technology over the last decades and the increasing availability of SBRT expertise and infrastructures have established SBRT as a safe, effective and efficient treatment option for ES NSCLC, which is today the standard of care for inoperable patients. While treatment of peripheral lesions indisputably results in excellent outcome and rare major side effects, centrally located lesions are more prone to develop treatment-related toxicity. The latter can be treated safely using adapted dose/fractionation regimes; however, research on the optimal relationship between fractionation schedules and tumor location is ongoing. In medically operable patients, surgical resection remains the preferred treatment, although SBRT has been shown to yield comparable results. SBRT is therefore a valid alternative for appropriately selected patients, however further randomized evidence is called for. Onward perspectives in SBRT may include the implementation of technological advances as well as treatment combinations (e.g., targeted substances) in order to further improve outcome and reduce toxicity.